Gossamer Prices the Recap, Not the NDA Hope

Summary: GOSS closed at $0.22 on May 26, 2026 after Gossamer launched a note exchange that would issue up to 317.6 million new shares, leave behind $72 million of new first-lien convertible debt, add up to 150 million warrants, and ask stockholders to authorize up to 4.0 billion shares plus a 1-for-10 to 1-for-150 reverse split. The market is talking about debt reduction. The filing reads like a bridge to the next capital raise. [1][2][3]

Opportunity Ranking

U.S.-only screen, per user scope. Repo-wide title scan found no prior GOSS article or slug match for this topic in the current run folder.

Rank	Idea	Discovery Lane	Why It May Be Best Now	Evidence Freshness	Catalyst Window	Near-Term >5% Move Case	Asymmetry	Main Reason to Reject
1	Gossamer prices the recap, not the NDA hope	U.S. biotech / debt exchange / dilution / reverse-split overhang	The common still trades at $0.22 even though the filed exchange can more than double the share count before warrants, keeps secured debt in the stack, and embeds a liquidity covenant that becomes easier only after a large equity raise. [1][2][3]	High. Core documents filed May 15 and May 18, 2026; price checked for May 26, 2026. [1][2][3]	High. Early tender deadline June 1, 2026; expected early settlement June 3, 2026; final expiry June 16, 2026; expected final settlement June 18, 2026. [2]	A >5% dump can happen on any sign that the exchange clears, the proxy arrives, or the market starts underwriting the next equity raise instead of the debt reduction headline.	High enough for a short, because the near-dated events are about capital structure, not just science.	Selected.
2	Lantheus prices a process, not a proposal	U.S. medtech / sale-process rumor / event-driven	`LNTH` closed at $100.06 on May 26, 2026 after a reported Curium approach, but there is still no company 8-K confirming a process or a formal bid. [4][5]	Medium. Quote is fresh, but the key catalyst is still press reporting rather than company disclosure. [4][5]	Medium-high. Any confirmation or silence would matter quickly.	A rumor premium can unwind more than 5% if no filing follows.	Moderate.	Rejected on source hierarchy. The setup is real, but primary-source evidence is weaker than `GOSS`.
3	Assertio offers certainty, but not enough spread	U.S. merger arb / cash tender	`ASRT` closed at $23.46 on May 26, 2026 against a live $23.50 cash tender that expires June 15, 2026. [6][7]	High. Terms are filed and the quote is current. [6][7]	High. Tender expiry is dated.	A move over 5% is not the base case. The spread is too thin.	Low.	Rejected on payoff. The deal may close, but the remaining gross edge is too small for the desk.

Selected opportunity: GOSS common stock, short.

Why this one now: The crucial dates are inside three weeks, the mechanics are filed, and the common still trades like the exchange is a solution rather than a restructuring waypoint.

Why it can jump or dump >5% soon: The early tender date is June 1, 2026 and the final settlement date is expected on June 18, 2026. The stock can dump on confirmed participation, a filed proxy, or any signal that the next financing is being underwritten off a much larger share base. It can also squeeze on FDA-path optimism. Either way, the move path is near-term and visible. [2][3]

What should surprise the reader: The same filing package that sells a debt reduction also asks investors to bless a share authorization jump from 700 million to 4.0 billion and a reverse split as steep as 1-for-150. That is not how companies talk when recap risk is over. [2]

The Setup

Gossamer is trying to buy time.

On May 18, 2026, the company launched an exchange offer for all of its $200 million of 5.00% convertible notes due 2027. Full participation would swap those notes into a package of new secured debt, stock or prefunded warrants, and early-tender warrants. The company says the exchange is intended to eliminate over $120 million of debt. That part is true. [2][3]

The part the common stock is not fully respecting is the price of the rescue.

Per $1,000 of old notes tendered before the early deadline, holders get $360 of new first-lien 7.50% notes, 1,588.2353 shares of common stock, and 750 purchase warrants. Across the full $200 million note stack, that means up to 317,647,058 new shares before any warrant exercise. Gossamer had 234,696,281 shares outstanding as of May 12, 2026. [2][3]

That math matters. Existing holders would go from owning 100% of the common to owning about 42.5% of the pro forma basic share count if the full equity leg is issued, before counting the 150 million early-tender warrants. Desk calculation. [2][3]

The Mispricing

The market appears to be pricing GOSS as if the exchange mainly removes a maturity wall and preserves the seralutinib option.

The better framing is harsher. The exchange shifts value toward creditors, subordinates the old capital structure to new first-lien paper, and still leaves common holders facing another financing round.

Confirmed facts

GOSS closed at $0.22 on May 26, 2026, after trading 13.23 million shares. Yahoo Finance also showed a market cap of roughly $53.7 million on the checked quote surface. [1]
As of March 31, 2026, Gossamer had $99.2 million of cash, cash equivalents, and marketable securities, $198.8 million of long-term convertible notes, and negative stockholders' equity of $161.5 million. [3]
First-quarter 2026 net loss was $46.7 million, and cash used in operating activities was $38.7 million. [3]
The company's independent auditor already included a going-concern explanatory paragraph in the 2025 financial statements, and the first-quarter 10-Q says future reports may do the same. [3]
The new note indenture will require minimum liquidity of $40 million, tested monthly starting with June 30, 2026, unless Gossamer completes one or more equity raises with at least $100 million of aggregate proceeds. [2]
Gossamer is also asking stockholders to approve an increase in authorized common shares from 700 million to 4.0 billion and a reverse split in a range from 1-for-10 to 1-for-150. [2]

Inference

This is not a finished recap. It is a creditor-backed bridge that still expects more common issuance.

Reasonable but unverified judgment

The common is still carrying too much value from the clinical narrative and not enough discount for the post-exchange share stack.

Price

Market Level	Value	Timestamp / Source	Why It Matters
`GOSS` close	$0.22	May 26, 2026, Yahoo Finance quote page [1]	Current price anchor
Day range	$0.21 to $0.24	Same check [1]	Confirms live volatility
Volume	13.23 million	Same check [1]	The tape is active enough to move hard on filings
Market cap	$53.7 million	Same check [1]	Shows how small the equity cushion already is
Shares outstanding	234.7 million	As of May 12, 2026, Form 10-Q [3]	Base for dilution math
New shares in full exchange	317.6 million	Exchange filing dated May 18, 2026 [2]	More than existing share count
New shares as % of current shares	135.3%	Desk calculation from the two lines above	Core dilution fact
Pro forma basic shares before warrant exercise	552.3 million	Desk calculation from the two lines above	Existing holders drop to about 42.5% ownership
Purchase warrants	150.0 million	Exchange filing dated May 18, 2026 [2]	Additional overhang from December 3, 2026 onward
Cash, cash equivalents, and marketable securities	$99.2 million	March 31, 2026, Form 10-Q [3]	Liquidity starting point
Long-term convertible notes	$198.8 million	March 31, 2026, Form 10-Q [3]	Debt stack before exchange
Q1 2026 net loss	$46.7 million	Form 10-Q [3]	Burn rate reminder
Q1 2026 operating cash use	$38.7 million	Form 10-Q [3]	Why more capital still matters

Positioning

I do not have verified live borrow-cost, short-interest, or listed-options open-interest data for GOSS in this run. I will not invent them.

The usable positioning evidence is elsewhere:

Holders of about 75.2% of the existing notes have already signed a transaction support agreement. [2]
The exchange still carries a 98% minimum participation condition, though that can be waived with the consent of the company and required supporting noteholders. [2]
Common holders are being asked to approve an enormous authorized-share increase and a very wide reverse-split range. [2]

That is enough to say the common stock is trading against a creditor-led process with more institutional control than the tape implies.

Catalyst

Catalyst 1: early tender on June 1, 2026. If participation looks strong, the market has to start underwriting the pro forma share count instead of the old one. [2]

Catalyst 2: expected early settlement on June 3, 2026. That is the first date the exchange can stop looking theoretical. [2]

Catalyst 3: final expiration on June 16, 2026 and expected final settlement on June 18, 2026. The recap window is measured in days, not quarters. [2]

Catalyst 4: the proxy. Gossamer has already said it will file a preliminary proxy seeking approval for the massive share authorization increase and the reverse split. [2]

Catalyst 5: the balance-sheet follow-through. The new note covenant structure explicitly becomes easier only after large equity financing. The more investors read that covenant, the less this looks like a clean rescue for common. [2]

The bull catalyst is the mid-June FDA pre-NDA Type B meeting referenced in the company's business update. That is real. It is also not the same thing as financing solved. [4]

Payoff Map

Facts: the exchange would issue more stock than currently exists, leave secured debt in place, and still point toward future equity financing. [2][3]

Inference: the common should trade lower once the market prices the post-exchange stack rather than the headline debt reduction.

Speculation, clearly marked: if the FDA meeting materially improves the perceived NDA path, the stock can temporarily squeeze despite the recap burden.

Trade expression: the cleanest expression is short common stock. I rejected a put-option recommendation because I did not verify a liquid, workable listed-options chain during this run.

Price Target and Probability Map

Scenario	Probability	Target / Level	Return / Payoff	Time Horizon	Conditions Required	Evidence Quality
Top Case	30%	$0.12	+45.5% on a short from $0.22	2 to 8 weeks	Exchange clears, proxy lands, and the market prices the recap as a bridge to more equity rather than a cure	Medium
Base Case	45%	$0.16	+27.3% on a short	2 to 6 weeks	Debt overhang eases, but dilution, secured debt, and the liquidity covenant cap the common	Medium
Bottom Case	25%	$0.32	-45.5% on a short	1 day to 6 weeks	FDA-path optimism, biotech momentum, or a squeeze dominates capital-structure math for a while	Medium
Invalidation / Stop Condition	n/a	Sustained trade above $0.34 or clear evidence of non-dilutive financing	n/a	Immediate on trigger	A credible financing or regulatory path has changed the equity case	Medium

Probability-weighted expected value: about $0.182, implying roughly 17.3% expected return on the short versus the $0.22 reference close.

Current market price / level: $0.22. [1]

Timestamp: Quote reference checked from the May 26, 2026 U.S. session. [1]

Primary instrument: GOSS common stock, short.

Alternative expressions considered: buying puts or put spreads; avoiding the trade until the proxy. Options were not selected because I did not verify live chain quality. Waiting is cleaner, but likely sacrifices the first repricing leg if the early-tender process tightens quickly.

Confidence: Medium-low.

What Would Prove This Wrong

The thesis fails if one of three things happens:

The FDA path becomes so much cleaner that investors can rationally finance through the recap instead of discounting it.
The exchange closes and the market decides the debt reduction is worth more to equity than the dilution costs.
Gossamer finds a large, credible financing or partnership path on materially better terms than the capital structure now implies.

A sustained move above $0.34, or evidence that the company can finance without another heavily dilutive common issuance, would invalidate the short.

Risk Audit

Strongest counterargument: The market may already have punished the common enough. At $0.22, the equity is already tiny. If the exchange removes the 2027 wall, the mid-June FDA meeting is constructive, and the Chiesi-backed development path remains intact, then common holders may decide the company bought enough time for the option value to matter again. [1][2][3][4]

Most fragile assumption: That the next financing step will be priced by the market before any major regulatory optimism takes over.

What the market may already know: That the recap is ugly, the dilution is large, and the company is buying time rather than solving commercialization today.

What could make the trade lose money even if the thesis is directionally right: Timing. A short can be correct on eventual value and still get hurt by a biotech squeeze around the FDA narrative or exchange headlines.

Liquidity / execution risks: The stock trades enough volume to move, but it is still a sub-dollar biotech. Gaps and sharp intraday reversals are normal. [1]

Leverage risks: This is a poor fit for leverage. The downside thesis is capital-structure based, but the upside squeeze risk is also real.

Information reliability risks: I did not verify live borrow data or option-chain liquidity in this run.

Invalidation trigger: Sustained trade above $0.34, or a clearly improved financing path that does not lean on the authorized-share increase.

Publish / revise / reject recommendation: Publish.

Bottom Line

GOSS is not really trading a completed repair. It is trading a hope that one messy recap buys enough time for the science to rescue the capital structure.

That is the wrong order. The filed exchange points first to dilution, secured debt, warrant overhang, a huge authorized-share request, and a reverse split. The FDA meeting may still matter. But the next dated events are recap events, not commercial ones. At $0.22, the cleaner trade is short common stock.

Best Trade Strategy

Direction: Short.

Preferred instrument: GOSS common stock.

Common-stock stance: Preferred. The thesis is directly about post-exchange equity value, dilution, and recap sequencing.

Options stance: Not preferred for this run. I did not verify liquid strikes, spreads, or open interest well enough to document a publish-ready options expression.

Take-profit zone: Start covering into $0.16, with a fuller target near $0.12 if the proxy and settlement path both confirm the dilution stack.

Stop / invalidation: Exit on sustained trade above $0.34 or on evidence of a meaningfully better-than-feared financing path.

Timeline: From now through the exchange dates of June 1, June 3, June 16, and June 18, 2026, then reassess around the FDA meeting path. [2][4]

Execution risks: Gap risk, borrow uncertainty, squeeze risk around biotech headlines, and sub-dollar trading behavior.

Do-not-trade conditions: Do not force the trade if borrow is unavailable, if the stock gaps above the invalidation zone on real financing news, or if the proxy materially softens the dilution terms.

Monitoring checklist:

Watch for exchange participation updates into June 1, 2026. [2]
Watch for the preliminary proxy covering authorized shares and reverse split. [2]
Watch for any financing, collaboration, or regulatory disclosure tied to seralutinib. [4]
Watch whether the stock starts trading through $0.20, $0.16, or $0.34 on real filings rather than chatty headlines. [1]

Research Quality Scorecard

Criterion	Score	Evidence Note
Market disagreement	5	The disagreement is specific: the market sees debt relief, while the filing package points to a recap that still leans on future equity. [2][3]
Evidence base	5	Core claims rely on the May 15 10-Q, the May 18 exchange filing, and a current quote surface. [1][2][3]
Positioning and flows	3	Creditor support is documented, but live borrow and derivative positioning were not verified. [2]
Catalyst path	5	The key dates are explicit and close: June 1, June 3, June 16, and June 18, 2026. [2]
Payoff architecture	4	The short has clear downside catalysts and a defined invalidation level, though biotech squeeze risk is meaningful.
Invalidation discipline	4	A sustained move above $0.34 or better-than-feared financing changes the thesis.
Differentiated insight	5	The non-obvious point is that the new note covenant package still points toward another equity raise, so the recap is not an end-state repair. [2]
Client value	4	Useful even without taking the trade because it shows how to read a biotech exchange offer through the common stock rather than through the debt headline.

Total Score: 35 / 40

Verdict: Publish-ready Deep Dive Trade Note

Sources

Illustration Prompt

Create a realistic, high-value, high-end elite, beautiful master editorial cover image for The Mispricing Desk about Gossamer Bio in late May 2026. The core tension is biotech hope versus creditor math. Stage the scene inside a dim institutional conference room after market close. On the table, place two stacks of paper under different light: one clean clinical deck labeled mid-June FDA meeting and one heavier legal-capital stack labeled exchange offer, 4.0bn authorized shares, and 1-for-10 to 1-for-150 reverse split. Let the capital-structure stack physically outweigh the clinical deck. Add a thin strip ticker or monitor showing GOSS 0.22 and another card showing 317.6m new shares beside 150m warrants. In the background, use subtle biotech cues such as a pulmonary scan or lab glass wall, but keep them secondary to the recap documents. Mood: forensic, expensive, skeptical, controlled. Palette: graphite, matte silver, paper white, muted hospital blue, and a faint emergency red accent. Style should feel like a Bloomberg Markets or Barron's cover shoot, not a biotech ad. No rockets, no generic up-charts, no glowing DNA clichés, no AI slop. Include a subtle but clear watermark or embossed text reading The Mispricing Desk.